Covington Reps AstraZeneca In $500M Amplimmune Buy
AstraZeneca PLC said on Monday it plans to buy privately held Amplimmune for $500 million, adding the Maryland company's early stage immunotherapy drugs aimed at boosting the British pharmaceutical giant's position...To view the full article, register now.
Already a subscriber? Click here to view full article